Bispecific T cell Engagers Workshop

Starts:  Sep 30, 2021 9:00 AM (ET)
Ends:  Oct 1, 2021 5:00 PM (ET)

ORGANIZERS

  • Elizabeth Budde, MD, PhD – City of Hope
  • Daniel S. Chen, MD, PhD – IGM Biosciences, Inc.
  • James L. Gulley, MD, PhD, FACP – National Cancer Institute

OVERVIEW

The Society for Immunotherapy of Cancer (SITC) invites you to attend the workshop, Bispecific T cell Engagers. This SITC workshop will focus on T cell engager biology and therapeutic strategies including target selection, therapeutic engineering and design features, cytotoxicity vs cytokine release, impact of the tumor microenvironment, and advances in conditionally-active binding.

Additionally, considerations related to dosing, schedule, sequencing and combination approaches for optimizing both endogenous and synthetic immunity will be discussed.

TARGET AUDIENCE

  • Basic, translational and clinical researchers from academic, industry, or government settings with an interest in developing, validating and applying T cell engager therapies for cancer treatment.

LEARNING OBJECTIVES

  • Compare and contrast cancer immunotherapy approaches employing endogenous or synthetic immunity.
  • Describe the biological and engineering considerations for development of T cell engagers.
  • Outline current clinical application of T cell engagers and identify challenges with their use in cancer immunotherapy.

Location

Hilton San Diego Mission Valley Hotel
901 Camino Del Rio S
San Diego, CA 92108